Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)

被引：0

作者：

Mirallas, O. ^{[1
]}

Marmolejo Castaneda, D. H. ^{[1
]}

Illescas, D. G. ^{[1
]}

Gomez-Puerto, D. ^{[2
]}

Berche, R. ^{[3
,4
]}

Calvo, A. H. ^{[5
]}

Vieito Villar, M. ^{[2
]}

Lorini, L. ^{[6
]}

Navarro, V. ^{[4
,7
]}

Assaf Pastrana, J. D. ^{[8
]}

Saavedra, O. ^{[9
]}

Alonso, G. ^{[10
]}

Aguilar Izquierdo, S. ^{[11
]}

Bescos, C. ^{[12
]}

Lorente, J. ^{[13
]}

Giralt, J. ^{[14
]}

Dienstmann, R. ^{[15
]}

Garralda, E. ^{[16
]}

Felip, E. ^{[17
]}

Brana, I. ^{[1
]}

机构：

[1] Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain

[2] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain

[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[4] Cellex Ctr, Barcelona, Spain

[5] Princess Margaret Canc Ctr, Med Oncol Phase Unit 1, Toronto, ON, Canada

[6] Azienda Osped Spedali Civili Brescia, Dipartimento Oncol Med, Brescia, Italy

[7] Vall dHebron Inst Oncol VHIO, Odyssey Grp, Barcelona, Spain

[8] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain

[9] Vall dHebron Univ Hosp, Res Unit Mol Therapy Canc UITM, Barcelona, Spain

[10] Vall dHebron Inst Oncol, Early Drug Dev Unit, Barcelona, Spain

[11] Vall dHebron Univ Hosp, Mol Prescreening Program Dept, Barcelona, Spain

[12] Vall dHebron Univ Hosp, Maxillofacial & Oral Surg, Barcelona, Spain

[13] Vall dHebron Univ Hosp, Otorhinolaryngol Dept, Barcelona, Spain

[14] Vall dHebron Univ Hosp, Radiotherapy Dept, Barcelona, Spain

[15] Grp Oncoclin, Oncol Data Sci Dept, Sao Paulo, Brazil

[16] Vall dHebron Univ Hosp, Early Drug Dev Grp, Barcelona, Spain

[17] Vall dHebron Univ Hosp, Lung Canc Unit, Med Oncol Serv, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.810

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

686P

引用

页码：S856 / S857

页数：2

共 50 条

[1] Efficacy of cetuximab based chemotherapy after immunotherapy treatments (IT) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
Hernando-Calvo, A.
Mirallas, O.
Marmolejo, D.
Felip, E.
Garralda, E.
Villacampa Javierre, G.
Feliu, B.
Martinez, S.
Gutierrez, R.
Dienstmann, R.
Brana, I.
ANNALS OF ONCOLOGY, 2019, 30 : 59 - 59
[2] Nutritional status (NS) as a strong predictor for immunotherapy (IT) outcome in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
Hernando-Calvo, A.
Mirallas, O.
Marmolejo Castaneda, D. H.
Vieito, M.
Santa Gadea, O. Saavedra
Gardeazabal, I.
Villacampa Javierre, G.
Aguilar, S.
Martin Liberal, J.
Bescos, C.
Lorente, J.
Giralt, J.
Benavente, S.
Fuentes, J. F.
Temprana-Salvador, J.
Alberola, M.
Dienstmann, R.
Garralda, E.
Felip, E.
Brana, I.
ANNALS OF ONCOLOGY, 2020, 31 : S671 - S672
[3] The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC).
Scheff, Nicole N.
Nilsen, Marci Lee
Li, Jinhong
Harris, Alexandria L.
Swartz, Andrew
Hsieh, Ronan Wenhan
Anderson, Jennifer Lynn
Ferris, Robert L.
Menk, Ashley
Delgoffe, Greg M.
Zandberg, Dan Paul
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) That Have Progressed on Prior Immunotherapy
Zandberg, D. P.
Chen, J.
Tatsuoka, C.
Normolle, D. P.
Ohr, J.
Isett, B.
Rahman, Z.
Fenton, M.
Gooding, W.
Vujanovic, L.
Bao, R.
Marsh, C.
Seastone, D.
Gorantla, V.
Pabla, S.
Conroy, J.
Ferris, R. L.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E4 - E4
[5] Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Chow, Laura Quan Man
Mehra, Ranee
Haddad, Robert I.
Mahipal, Amit
Weiss, Jared
Berger, Raanan
Eder, Joseph Paul
Burtness, Barbara
Tahara, Makoto
Keam, Bhumsuk
Le, Dung T.
Muro, Kei
Geva, Ravit
Chung, Hyun Cheol
Lin, Chia-Chi
Ayers, Mark
Aurora-Garg, Deepti
Lunceford, Jared K.
Cheng, Jonathan D.
Seiwert, Tanguy Y.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[6] Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt)
Hernando-Calvo, A.
Mirallas, O.
Marmolejo, D.
Felip, E.
Villacampa Javierre, G.
Garralda, E.
Gutierrez, R.
Feliu, B.
Martinez, S.
Dienstmann, R.
Brana, I.
ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
[7] Genomic characteristics and immunotherapy outcomes in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Park, J. C.
Cortes, M. Useche
Durbeck, J.
Clark, J. R.
Zhao, Y.
Saladi, S. V.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S856 - S856
[8] Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Lasniska, Izabela
Kolenda, Tomasz
Teresiak, Anna
Lamperska, Katarzyna M.
Galus, Lukasz
Mackiewicz, Jacek
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (03) : 290 - 303
[9] Evaluation of systemic inflammatory response (SIR) markers in recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC)
Pogorzelski, M.
Hilser, T.
Ting, S.
Vossebein, I
Gauler, T. C.
Abendroth, A.
Lang, S.
Stuck, B.
Abu-Jawad, J.
Stuschke, M.
Schmid, K. W.
Schuler, M.
Kasper, S.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 307 - 308
[10] Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC)
Bauman, Julie E.
Arias-Pulido, Hugo
Lee, Sang-Joon
Considine, Michael
Fekrazad, M. Houman
Howard, Jason
Bishop, Justin A.
Olson, Garth T.
Jones, Dennie V.
Fertig, Elana J.
Chung, Christine H.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →